pre-IPO PHARMA

psioxus-therapeutics PRESS RELEASE ARCHIVE

Jan 5, 2023

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics


Aug 11, 2022

PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer


Apr 7, 2021

PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration


Mar 5, 2020

PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer


Mar 5, 2020

PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer



Nov 26, 2018


Nov 15, 2018

PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors


Jun 4, 2018

PsiOxus Therapeutics Appoints Melissa Epperly as Chief Financial Officer


Jun 4, 2018

PsiOxus Therapeutics Appoints Melissa Epperly as Chief Financial Officer


Dec 12, 2017

PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA



Dec 12, 2017

PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA


Aug 17, 2017

PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence


Aug 17, 2017

PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence


Jun 20, 2017

PsiOxus Therapeutics amplía sus operaciones en Oxford, Reino Unido y Filadelfia, Estados Unidos


Jun 20, 2017

PsiOxus Therapeutics élargit ses activités à Oxford, au Royaume-Uni et à Philadelphie, États-Unis



Jun 20, 2017

PsiOxus Therapeutics erweitert seine Geschäftsaktivitäten in Oxford, GB, und Philadelphia, USA


Jun 14, 2017

PsiOxus Therapeutics Expands Operations in Both Oxford, UK and Philadelphia, USA


Dec 20, 2016

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors


Sep 16, 2016

PsiOxus Therapeutics Announce Executive Team Reorganization with Two New C Level Appointments in the US


Sep 16, 2016

PsiOxus Therapeutics Announce Executive Team Reorganization with Two New C Level Appointments in the US



Jun 30, 2016

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev


Jun 30, 2016

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev


Jun 30, 2016

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev


Apr 14, 2016

Parker Institute for Cancer Immunotherapy and PsiOxus Therapeutics Announce Intention to Collaborate on Tumor-Specific Immuno-Gene Therapy


Apr 14, 2016

Parker Institute for Cancer Immunotherapy and PsiOxus Therapeutics Announce Intention to Collaborate on Tumor-Specific Immuno-Gene Therapy



Mar 10, 2016

PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study


Mar 10, 2016

PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study


Jan 7, 2016

PsiOxus Therapeutics Appoints Dr Paolo Paoletti as Chairman of the Board


Jan 7, 2016

PsiOxus Therapeutics Appoints Dr Paolo Paoletti as Chairman of the Board


Dec 16, 2015

PsiOxus Therapeutics Initiates Combination Study of Merck’s Keytruda with Oncolytic Virus Enadenotucirev



Dec 16, 2015

PsiOxus Therapeutics Initiates Combination Study of Merck’s Keytruda with Oncolytic Virus Enadenotucirev


May 19, 2015

PsiOxus Therapeutics Raises a £25M Series C Investment to Progress Oncolytic Virus Plus Checkpoint Inhibitor Combination Study in Metastatic Colorectal Cancer


May 19, 2015

PsiOxus Therapeutics Raises a £25M Series C Investment to Progress Oncolytic Virus Plus Checkpoint Inhibitor Combination Study in Metastatic Colorectal Cancer


Apr 16, 2015

PsiOxus Therapeutics to Present Promising New Data on Novel Oncolytic Immunoncology Platform at AACR 2015


Apr 16, 2015

PsiOxus Therapeutics Expands Clinical Studies for Immuno-Oncolytic Treatment Following Positive Response to Intravenous Delivery



Apr 16, 2015

PsiOxus Therapeutics to Present Promising New Data on Novel Oncolytic Immunoncology Platform at AACR 2015


Apr 16, 2015

PsiOxus Therapeutics to Present Promising New Data on Novel Oncolytic Immunoncology Platform at AACR 2015


Apr 16, 2015

PsiOxus Therapeutics Expands Clinical Studies for Immuno-Oncolytic Treatment Following Positive Response to Intravenous Delivery


Jun 17, 2014

PsiOxus Therapeutics Initiates ‘OCTAVE’ Ovarian Cancer Study for Oncolytic Vaccine Enadenotucirev


Jun 17, 2014

PsiOxus Therapeutics Initiates ‘OCTAVE’ Ovarian Cancer Study for Oncolytic Vaccine Enadenotucirev



Jun 17, 2014

PsiOxus Therapeutics Initiates ‘OCTAVE’ Ovarian Cancer Study for Oncolytic Vaccine Enadenotucirev


Jun 3, 2014

PsiOxus Therapeutics Announces Positive Study Results of Oncolytic Vaccine Enadenotucirev at 2014 ASCO Annual Meeting


Jun 3, 2014

PsiOxus Therapeutics Announces Positive Study Results of Oncolytic Vaccine Enadenotucirev at 2014 ASCO Annual Meeting


May 13, 2014

PsiOxus Therapeutics to Release Study Results of Oncolytic Vaccine Enadenotucirev in Cancer Patients


May 13, 2014

PsiOxus Therapeutics to Release Study Results of Oncolytic Vaccine Enadenotucirev in Cancer Patients



Mar 20, 2013

PsiOxus Therapeutics Comments on Phase III Results from Amgen’s Oncolytic Vaccine


Mar 20, 2013

PsiOxus Therapeutics Comments on Phase III Results from Amgen’s Oncolytic Vaccine


Mar 4, 2013

PsiOxus Therapeutics Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102


Mar 4, 2013

PsiOxus Therapeutics Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102


Jan 17, 2013

CORRECTING and REPLACING DTRA Awards US$3.3M Contract to PsiOxus Therapeutics to Develop Biodefence Vaccine Adjuvants



Nov 5, 2012

UK Government Awards £1.7M Grant to PsiOxus Therapeutics for Second Phase I/II Clinical Trial of Cancer Vaccine


Nov 5, 2012

UK Government Awards £1.7M Grant to PsiOxus Therapeutics for Second Phase I/II Clinical Trial of Cancer Vaccine


Jul 9, 2012

PsiOxus Therapeutics Secures £22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine


Jul 9, 2012

PsiOxus Therapeutics Secures £22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine


May 24, 2012

PsiOxus Therapeutics Moves into New Facilities on Milton Park to Accommodate Expansion



May 24, 2012

PsiOxus Therapeutics Moves into New Facilities on Milton Park to Accommodate Expansion


Mar 17, 2011

PsiOxus Therapeutics Initiates Phase II Clinical Study of Wasting Disease Therapeutic MT-102


Mar 17, 2011

PsiOxus Therapeutics Initiates Phase II Clinical Study of Wasting Disease Therapeutic MT-102


Dec 15, 2010

Myotec Therapeutics Completes Merger with Hybrid BioSystems to Form PsiOxus Therapeutics


Google Analytics Alternative